The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.
AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractThe composition of the multidisciplinary team (MDT) that treats lung cancer varies by region and practice setting but generally includes a thoracic medical oncologist, a thoracic surgeon, a thoracic radiation oncologist, and an interventional radiologist, as well as a pathologist, pulmonologist, and specialist nurses. Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. The most recent National Comprehensive Cancer Network (NCCN) guidelines also recommend sequential EGFR and ALK testing for patients with a diagnosis of recurrent or metastatic adenocarcinoma, large cell carcinoma, or not otherwise specified histology, and simultaneous molecular screening has also been proposed. Here, we explore potential challenges for the MDT implied by the move toward personalized therapy in NSCLC and the increasing need for molecular diagnoses, and anticipate how the working roles and responsibilities of team members may develop to accommodate them.
CitationThe impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. 2012: Lung Cancer
- PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
- Authors: Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E
- Issue date: 2013 Apr
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
- Authors: Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T
- Issue date: 2011 Mar
- Treatment of ALK-positive non-small cell lung cancer.
- Authors: Bang YJ
- Issue date: 2012 Oct
- Personalized medicine for non-small-cell lung cancer.
- Authors: Mok TS, Zhou Q, Leung L, Loong HH
- Issue date: 2010 Oct
- Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
- Authors: Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N
- Issue date: 2011 May